FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More

Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non—small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.